Mylan has now received regulatory approval from the Drugs Controller General of India for its Desrem (remdesivir) 100mg/vial for restricted emergency use in the country, as part of the accelerated approval process to address urgent unmet needs amid COVID-19.
Desrem will be available to patients this month and has been priced at INR4,800 ($64), roughly in the price range...




